依巴斯汀治疗慢性特发性荨麻疹的疗效及安全性

Efficacy and safety of ebastine on chronic idiopathic urticaria

目的:观察依巴斯汀治疗慢性特发性荨麻疹患者的疗效及安全性。方法:对68例慢性特发性荨麻疹患者应用依巴斯汀10 mg,qd,连续治疗4周,于治疗后2,4和8周时复诊观察记录疗效及不良反应。结果:用药2周时痊愈32例(47．1%),显效41例(显效率60．3%);4周时痊愈38例(55．9%),显效46例(显效率67．6%);8周时痊愈41例(60．3%),显效48例(显效率70．1%)。2周时3例出现轻度头晕(4．4%),4周复诊时消失,8周时无明显不良反应。结论:依巴斯汀治疗慢性特发性荨麻疹安全有效。

Objective ： To evaluate the efficacy and safety of ebastine in the treatment of chronic idiopathic urticaria. Methods ：68 patients with chronic idiopathic urticaria were randomized to orally receive ebastine 10 mg qd for 4 weeks. The patients were followed up at the end of 2, 4 and 8 weeks after the treatment. Results： In the 2-week therapy, the cure rate was 47. 1% （32/68） and effectual rate 60. 3% （41/68） ; in the 4-week therapy, the cure rate was 55.9% （38/6） and effectual rate 67.6% （46/68） ; in the 8-week therapy, the cure rate was 60. 3% （41/68） and effectual rate 70. 1% （48/ 68）. Three patients complained slight headache in 2 weeks after the treatment. However, the headache vanished when the patients continued the treatment. No serious adverse events were reported. Conclution： Ebastine offers a therapeutic option in the treatment of chronic idiopathic urticaria.